STANDARD BIOTOOLS INC
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
LAB$0.69+9.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
INDEX TO EXHIBITS
| ExhibitNumber | Description | Incorporatedby ReferenceFrom Form | File Number | Incorporatedby ReferenceFrom ExhibitNumber | Date Filed |
|---|---|---|---|---|---|
| 2.1†† | Agreement and Plan of Merger, dated January 28, 2014, by and among DVS Sciences, Inc., Standard BioTools Inc. (formerly Fluidigm Corporation), Dawid Merger Sub, Inc. and Shareholder Representative Services LLC. | 8-K | 001-34180 | 2.1 | 1/29/2014 |
| 2.2†† | Merger Agreement, dated as of March 28, 2021, as amended by the First Amendment thereto dated as of May 12, 2021 and the Second Amendment thereto dated as of July 15, 2021, by and among SomaLogic, Inc. (CM Life Sciences II, Inc.), S-Craft Merger Sub, Inc., and SomaLogic Operating Co., Inc. (formerly SomaLogic, Inc.). | S-4/A | 333-256127 | 2.1 | 8/5/2021 |
| 2.3† | Agreement and Plan of Merger, dated as of July 25, 2022, by and among SomaLogic, Inc., Panther Merger Subsidiary I, LLC, Panther Merger Subsidiary I, LLC, Palamedrix, Inc., and Securityholder Representative Services LLC. | 8-K | 001-40090 | 2.1 | 7/27/2022 |
| 2.4†† | Agreement and Plan of Merger, dated as of October 4, 2023, by and among Standard BioTools Inc., SomaLogic, Inc., and Martis Merger Sub, Inc. | 8-K | 001-34180 | 2.1 | 10/4/2023 |
| 3.1 | Eighth Amended and Restated Certificate of Incorporation of Standard BioTools Inc. (formerly Fluidigm Corporation). | 10-K | 001-34180 | 3.1 | 3/28/2011 |
| 3.2 | Amended and Restated Bylaws of Standard BioTools Inc. (formerly Fluidigm Corporation). | S-8 | 333-264086 | 4.8 | 4/1/2022 |
| 3.3 | Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation of Standard BioTools Inc. (formerly Fluidigm Corporation). | S-8 | 333-264086 | 4.3 | 4/1/2022 |
| 3.4 | Second Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation of Standard BioTools Inc. | 8-K | 001-34180 | 3.1 | 1/5/2024 |
| 3.5 | Certificate of Designations of Rights, Preferences and Privileges of Series B-1 Convertible Preferred Stock. | 8-K | 001-34180 | 3.6 | 4/5/2022 |
| 3.6 | Certificate of Designations of Rights, Preferences and Privileges of Series B-2 Convertible Preferred Stock. | 8-K | 001-34180 | 3.7 | 4/5/2022 |
| 3.7 | Certificate of Elimination of Series B-1 Convertible Preferred Stock. | 8-K | 001-34180 | 3.1 | 3/18/2024 |
| 3.8 | Certificate of Elimination of Series B-2 Convertible Preferred Stock. | 8-K | 001-34180 | 3.2 | 3/18/2024 |
| 4.1 | Specimen Stock Certificate of Standard BioTools Inc. | S-8 | 333-264086 | 4.1 | 4/1/2022 |
| 4.2 | Description of Securities. | Filed herewith | |||
| 4.3 | Indenture, dated February 4, 2014, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and U.S. Bank National Association. | 8-K | 001-34180 | 4.1 | 2/4/2014 |
| ExhibitNumber | Description | Incorporatedby ReferenceFrom Form | File Number | Incorporatedby ReferenceFrom ExhibitNumber | Date Filed |
|---|---|---|---|---|---|
| 4.4 | First Supplemental Indenture, dated February 4, 2014, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and U.S. Bank National Association. | 8-K | 001-34180 | 4.2 | 2/4/2014 |
| 4.5 | Form of Global Note (included in Exhibit 4.4). | 8-K | 001-34180 | 4.3 | 2/4/2014 |
| 4.6 | Indenture, dated November 22, 2019, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and U.S. Bank National Association. | 8-K | 001-34180 | 4.1 | 11/22/2019 |
| 4.7 | Form of 5.25% Convertible Senior Note due 2024 (included in Exhibit 4.6). | 8-K | 001-34180 | 4.2 | 11/22/2019 |
| 4.8 | Warrant Agreement, dated as of February 22, 2021, by and between SomaLogic, Inc. (formerly CM Life Sciences II Inc.) and Continental Stock Transfer & Trust Company. | 8-K | 001-40090 | 10.1 | 2/26/2021 |
| 4.9 | Form of SomaLogic, Inc. Subscription Agreement. | 8-K | 001-40090 | 10.1 | 3/29/2021 |
| 10.1# | Form of Indemnification Agreement entered into by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and certain of its officers and directors. | S-1/A | 333-170965 | 10.1 | 1/28/2011 |
| 10.2# | Form of Indemnification Agreement entered into by and between Standard BioTools Inc. and certain of its officers and directors. | 10-K | 001-40090 | 10.2 | 3/1/2024 |
| 10.3 | Lease, dated as of March 20, 2019, by and between AP3-SF3 CT North, LLC and Standard BioTools Inc. (formerly Fluidigm Corporation). | 10-Q | 001-34180 | 10.1 | 5/7/2019 |
| 10.4 | First Amendment to Lease, dated as of April 26, 2019, by and between AP3-SF3 CT North, LLC and Standard BioTools Inc. (formerly Fluidigm Corporation). | 10-Q | 001-34180 | 10.2 | 5/7/2019 |
| 10.5 | Second Amendment to Lease, dated as of February 25, 2020, by and between AP3-SF3 CT North, LLC and Standard BioTools Inc. (formerly Fluidigm Corporation). | 10-K | 001-34180 | 10.2B | 2/25/2021 |
| 10.6† | Office Lease, dated as of August 17, 2015, by and among Rodick Equities Inc., Standard BioTools Canada Inc. (formerly Fluidigm Canada Inc.), and Standard BioTools Inc. (formerly Fluidigm Corporation). | 10-Q | 001-34180 | 10.1 | 11/9/2015 |
| 10.7 | Tenancy for Flatted Factory Space, dated as of July 27, 2005, by and between JTC Corporation and Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.). | S-1 | 333-170965 | 10.20 | 12/3/2010 |
| 10.8 | Offer of Tenancy for Facility Lease, dated as of October 14, 2013, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and SBC Institutional Trust Services (Singapore) Limited, as Trustee of Ascendas Real Estate Investment Trust. | 10-K | 001-34180 | 10.21 | 3/12/2014 |
| 10.9 | Offer of Tenancy for Lease of Additional Space, dated as of April 2, 2015, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and HSBC Institutional Trust Services (Singapore) Limited, as Trustee of Ascendas Real Estate Investment Trust. | 10-Q | 001-34180 | 10.1 | 8/10/2015 |
| ExhibitNumber | Description | Incorporatedby ReferenceFrom Form | File Number | Incorporatedby ReferenceFrom ExhibitNumber | Date Filed |
|---|---|---|---|---|---|
| 10.10 | Lease Agreement, dated as of November 19, 2020, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and HSBC Institutional Trust Services (Singapore) Limited as Trustee of Ascendas Real Estate Investment Trust. | 10-Q | 001-34180 | 10.2 | 8/6/2021 |
| 10.11 | Lease Agreement, dated as of June 8, 2021, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and HSBC Institutional Trust Services (Singapore) Limited as Trustee of Ascendas Real Estate Investment Trust. | 10-Q | 001-34180 | 10.3 | 8/6/2021 |
| 10.12 | Lease Agreement, dated as of December 13, 2021, by and between Standard BioTools Singapore Pte. Ltd. (formerly Fluidigm Singapore Pte. Ltd.) and HSBC Institutional Trust Services (Singapore) Limited as Trustee of Ascendas Real Estate Investment Trust. | 10-K | 001-34180 | 10.5D | 3/8/2022 |
| 10.13 | Sublease, dated as of August 30, 2022, by and between Standard BioTools Inc. and CIRC Bio, Inc. | 10-Q | 001-34180 | 10.1 | 11/9/2022 |
| 10.14 | Sublease, dated as of February 28, 2023, by and between Standard BioTools Inc. and First Databank, Inc. | 10-Q | 001-34180 | 10.1 | 5/9/2023 |
| 10.15†† | Lease Agreement, dated February 10, 2022, by and between SomaLogic Operating Co., Inc. and Louisville 1 Industrial Owner, LLC. | 8-K | 001-40090 | 10.1 | 2/16/2022 |
| 10.16†† | Lease Agreement, dated February 10, 2022, by and between SomaLogic Operative Co., Inc. and Louisville 2 Industrial Owner, LLC. | 8-K | 001-40090 | 10.2 | 2/16/2022 |
| 10.17† | Second Amended and Restated License Agreement, dated as of May 1, 2004, by and between California Institute of Technology and Standard BioTools Inc. (formerly Fluidigm Corporation). | 10-Q | 001-34180 | 10.2 | 11/9/2020 |
| 10.18† | First Addendum to Second Amended and Restated License Agreement, dated as of March 29, 2007, by and between California Institute of Technology and Standard BioTools Inc. (formerly Fluidigm Corporation). | 10-Q | 001-34180 | 10.2A | 11/9/2020 |
| 10.19† | Co-Exclusive License Agreement, dated as of October 15, 2000, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Mycometrix Corporation). | 10-Q | 001-34180 | 10.3 | 11/9/2020 |
| 10.20† | First Amendment to Co-Exclusive License Agreement, dated as of October 15, 2000, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Mycometrix Corporation). | 10-Q | 001-34180 | 10.3A | 11/9/2020 |
| 10.21† | Co-Exclusive License Agreement, dated as of October 15, 2000, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Mycometrix Corporation). | 10-Q | 001-34180 | 10.4 | 11/9/2020 |
| ExhibitNumber | Description | Incorporatedby ReferenceFrom Form | File Number | Incorporatedby ReferenceFrom ExhibitNumber | Date Filed |
|---|---|---|---|---|---|
| 10.22† | Co-Exclusive License Agreement, dated as of October 15, 2000, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Mycometrix Corporation). | 10-Q | 001-34180 | 10.5 | 11/9/2020 |
| 10.23† | Letter Agreement, dated as of December 22, 2004, by and between President and Fellows of Harvard College and Standard BioTools Inc. (formerly Fluidigm Corporation). | 10-Q | 001-34180 | 10.6 | 11/9/2020 |
| 10.24 | Purchase Agreement, dated as of November 20, 2019, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and Barclays Capital Inc., as representative of the several initial purchasers named in Schedule I thereto. | 8-K | 001-34180 | 10.1 | 11/22/2019 |
| 10.25† | Solicitation/Contract/Order for Commercial Items, dated as of July 30, 2020, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and National Institutes of Health, as amended on September 28, 2020. | 10-Q | 001-34180 | 10.1 | 11/9/2020 |
| 10.26† | Amendment of Solicitation/Modification of Contract, dated as of May 10, 2021, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and the National Institutes of Health. | 10-Q | 001-34180 | 10.1 | 8/6/2021 |
| 10.27† | Amendment of Solicitation/Modification of Contract, dated as of September 29, 2021, by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and the National Institutes of Health. | 10-Q | 001-34180 | 10.1 | 11/9/2021 |
| 10.28 | Private Placement Warrants Purchase Agreement, dated February 22, 2021, by and among SomaLogic, Inc. (formerly CM Life Sciences II Inc.), CMLS Holdings LLC and certain directors (and/or entities controlled by them) named in Exhibit A thereto. | 8-K | 001-40090 | 10.4 | 2/26/2021 |
| 10.29 | Registration Rights Agreement, dated as of January 23, 2022, by and between Standard BioTools Inc. (formerly Fluidigm Corporation), Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P., Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Drawdown (Aggregator) LP. | 8-K | 001-34180 | 10.5 | 1/24/2022 |
| 10.30 | SomaLogic, Inc. (formerly CM Life Sciences II Inc.) Form of Amended and Restated Registration Rights Agreement. | 8-K | 001-40090 | 10.6 | 3/29/2021 |
| 10.31# | Standard BioTools Inc. (formerly Fluidigm Corporation) Executive Bonus Plan. | 10-Q | 001-34180 | 10.25 | 3/28/2011 |
| 10.32# | Form of Amended and Restated Employment and Severance Agreement entered into by and between Standard BioTools Inc. (formerly Fluidigm Corporation) and each of its executive officers. | 8-K | 001-34180 | 10.14 | 12/11/2012 |
| 10.33# | Standard BioTools Inc. (formerly Fluidigm Corporation) Form of Retention Letter. | 8-K | 001-34180 | 10.10 | 1/24/2022 |
| 10.34# | Michael Egholm Offer Letter. | 8-K | 001-34180 | 10.7 | 1/24/2022 |
| 10.35# | Alex Kim Offer Letter. | 8-K | 001-34180 | 10.9 | 1/24/2022 |
| ExhibitNumber | Description | Incorporatedby ReferenceFrom Form | File Number | Incorporatedby ReferenceFrom ExhibitNumber | Date Filed |
|---|---|---|---|---|---|
| 10.36# · Sean Mackay Offer Letter. · Filed Herewith | |||||
| 10.37# | Standard BioTools Inc. (formerly Fluidigm Corporation) 2020 Change of Control and Severance Plan. | 10-Q | 001-34180 | 10.5 | 8/7/2020 |
| 10.38# | Standard BioTools Inc. 2023 Change of Control and Severance Plan. | 8-K | 001-34180 | 10.1 | 7/28/2023 |
| 10.39# | Standard BioTools Inc. 2023 Change of Control and Severance Plan Participation Agreement, dated as of July 27, 2023, by and between Standard BioTools Inc. and Michael Egholm, Ph.D. | 8-K | 001-34180 | 10.2 | 7/28/2023 |
| 10.40# | 2024 Change of Control and Severance Plan and Participation Agreement. | 8-K | 001-34180 | 10.1 | 8/30/2024 |
| 10.41# | Standard BioTools Inc. (formerly Fluidigm Corporation) 2009 Equity Incentive Plan, as amended. | S-1 | 333-170965 | 10.3 | 12/3/2010 |
| 10.42# | Standard BioTools Inc. (formerly Fluidigm Corporation) 2009 Equity Incentive Plan Forms of Agreements. | S-1 | 333-170965 | 10.3A | 12/3/2010 |
| 10.43# | Amendments to the Standard BioTools Inc. 2011 Equity Incentive Plan, the Standard BioTools Inc. (formerly Fluidigm Corporation) 2009 Equity Incentive Plan and the Standard BioTools Inc. (formerly DVS Sciences, Inc.) 2010 Equity Incentive Plan. | 8-K | 001-34180 | 10.2 | 8/2/2017 |
| 10.44# | Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan. | 8-K | 001-34180 | 10.1 | 1/5/2024 |
| 10.45# | Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan Forms of Agreements for U.S. Participants. | SC TO-I | 005-86635 | (d)(2) | 8/23/2017 |
| 10.46# | Rules of the Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan for Restricted Stock Unit Awards Granted to French Participants. | SC TO-I | 005-86635 | (d)(3) | 8/23/2017 |
| 10.47# | Rules of the Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan for Options Granted to French Participants. | SC TO-I | 005-86635 | (d)(4) | 8/23/2017 |
| 10.48# | UK Sub-Plan to the Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan. | SC TO-I | 005-86635 | (d)(5) | 8/23/20217 |
| 10.49# | Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan Form of Restricted Stock Unit Agreement for Non-U.S. Participants. | SC TO-I | 005-86635 | (d)(6) | 8/23/2017 |
| 10.50# | Standard BioTools Inc. (formerly Fluidigm Corporation) 2011 Equity Incentive Plan Form of Stock Option Agreement for Non-U.S. Participants. | SC TO-I | 005-86635 | (d)(7) | 8/23/2017 |
| 10.51# | Standard BioTools Inc. 2011 Equity Incentive Plan Form of PSU Award Agreement. | 8-K | 001-34180 | 10.3 | 7/28/2023 |
| 10.52# | Standard BioTools Inc. (formerly Fluidigm Corporation) 2017 Inducement Award Plan and Form of Agreements. | 8-K | 001-34180 | 10.1 | 1/11/2017 |
| ExhibitNumber | Description | Incorporatedby ReferenceFrom Form | File Number | Incorporatedby ReferenceFrom ExhibitNumber | Date Filed |
|---|---|---|---|---|---|
| 10.53# | Standard BioTools Inc. (formerly Fluidigm Corporation) Amended and Restated 2017 Employee Stock Purchase Plan. | 8-K | 001-34180 | 10.1 | 6/24/2020 |
| 10.54# | Standard BioTools Inc. 2022 Inducement Equity Incentive Plan. | S-8 | 333-264086 | 4.9 | 4/1/2022 |
| 10.55# | Standard BioTools Inc. 2022 Inducement Equity Incentive Plan Form of Notice of Stock Option Grant and Stock Option Agreement. | S-8 | 333-264086 | 99.1 | 4/1/2022 |
| 10.56# | Standard BioTools Inc. 2022 Inducement Equity Incentive Plan Form of Notice of Restricted Stock Unit Grant and Restricted Stock Unit Agreement. | S-8 | 333-264086 | 99.2 | 4/1/2022 |
| 10.57# | SomaLogic, Inc. 2009 Equity Incentive Plan. | S-4 | 333-256127 | 10.7 | 5/14/2021 |
| 10.58# | Form of Non-Statutory Stock Option Agreement under the SomaLogic, Inc. 2009 Equity Incentive Plan. | S-4 | 333-256127 | 10.8 | 5/14/2021 |
| 10.59# | Form of Incentive Stock Option Agreement under the SomaLogic, Inc. 2009 Equity Incentive Plan. | S-4 | 333-256127 | 10.9 | 5/14/2021 |
| 10.60# | SomaLogic, Inc. 2017 Equity Incentive Plan. | S-4 | 333-256127 | 10.10 | 5/14/2021 |
| 10.61# | Form of Option Agreement (Incentive Stock Option or Non-statutory Stock Option) under the SomaLogic, Inc. 2017 Equity Incentive Plan. | S-4 | 333-256127 | 10.11 | 5/14/2021 |
| 10.62# | SomaLogic, Inc. 2021 Omnibus Incentive Plan. | S-4/A | 333-256127 | 10.1 | 8/5/2021 |
| 10.63# | SomaLogic, Inc. Employee Stock Purchase Plan. | S-4/A | 333-256127 | 10.2 | 8/5/2021 |
| 10.64# | Form of Stock Appreciation Rights Agreement pursuant to the SomaLogic, Inc. 2021 Omnibus Incentive Plan. | S-4/A | 333-256127 | 10.3 | 6/5/2021 |
| 10.65# | Form of Incentive Stock Option Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan. | S-4/A | 333-256127 | 10.4 | 6/5/2021 |
| 10.66# | Form of Restricted Stock Unit Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan. | S-4/A | 333-256127 | 10.5 | 6/5/2021 |
| 10.67# | Form of Restricted Stock Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan. | S-4/A | 333-256127 | 10.6 | 6/5/2021 |
| 10.68# | Form of Non-Qualified Stock Option Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan. | S-4/A | 333-256127 | 10.7 | 6/5/2021 |
| 10.69 | Third Amendment to Collaboration Agreement, dated September 21, 2023, by and among SomaLogic, Inc., Illumina Cambridge, Ltd., and Illumina, Inc. | 10-Q | 001-40090 | 10.1 | 11/8/2023 |
| 10.70 | Second Amendment to Collaboration Agreement, dated June 15, 2023, by and among SomaLogic, Inc., Illumina Cambridge, Ltd., and Illumina Inc. | 10-Q | 001-40090 | 10.4 | 8/14/2023 |
| 10.71 | First Amendment to Collaboration Agreement, dated November 14, 2022, by and among SomaLogic, Inc., Illumina Cambridge, Ltd. and Illumina, Inc. | 10-K | 001-39796 | 10.38 | 3/28/2023 |
| ExhibitNumber | Description | Incorporatedby ReferenceFrom Form | File Number | Incorporatedby ReferenceFrom ExhibitNumber | Date Filed |
|---|---|---|---|---|---|
| 10.72† | Collaboration Agreement, dated December 31, 2021, by and among SomaLogic, Inc., Illumina Cambridge, Ltd. and Illumina, Inc. | 10-K | 001-40090 | 10.36 | 3/29/2022 |
| 10.73 | Second Amendment to Supply Agreement, dated April 11, 2023, by and between SomaLogic, Inc. and Agilent Technologies, Inc. | 10-Q | 001-40090 | 10.1 | 8/14/2023 |
| 10.74† | Supply Agreement, dated April 8, 2019, by and between SomaLogic, Inc. and Agilent Technologies, Inc., as amended by that certain First Amendment to Supply Agreement, dated October 1, 2021, by and between SomaLogic, Inc. and Agilent Technologies, Inc. | 10-K | 001-40090 | 10.34 | 3/29/2022 |
| 10.75# | Standard BioTools Inc. Nonemployee Director Compensation Policy. | 10-K/A | 001-40090 | 10.96 | 4/26/2024 |
| 10.76 | Exchange Agreement, dated March 18, 2024, by and between Standard BioTools Inc. and Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P., Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP. | 8-K | 001-40090 | 10.1 | 3/18/2024 |
| 19.1 | Standard BioTools Inc. Insider Trading Policy | Filed herewith | |||
| 21.1 | Subsidiaries of Standard BioTools Inc. | Filed herewith | |||
| 23.1 | Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm. | Filed herewith | |||
| 24.1 | Power of Attorney (contained in the signature page to this Form 10-K). | Filed herewith | |||
| 31.1 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of Chief Executive Officer. | Filed herewith | |||
| 31.2 | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of Chief Financial Officer. | Filed herewith | |||
| 32.1~ | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Chief Executive Officer. | Filed herewith | |||
| 32.2~ | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Chief Financial Officer. | Filed herewith | |||
| 97.1# | Standard BioTools Inc. Clawback Policy. | 10-K | 001-40090 | 97.1 | 3/1/2024 |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | Filed herewith | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document | Filed herewith | |||
| ExhibitNumber | Description | Incorporatedby ReferenceFrom Form | File Number | Incorporatedby ReferenceFrom ExhibitNumber | Date Filed |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Filed herewith | |||
Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.
† Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv) or pursuant to an order granted by the Securities and Exchange Commission for confidential treatment.
†† The schedules and exhibits to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K.
~ In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that Standard BioTools Inc. specifically incorporates it by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.